-
1
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
National Cancer Institute of Canada Clinical Trials Group
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
2
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-957.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
3
-
-
77953541527
-
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre randomised placebo-controlled phase 3 study
-
SATURN Investigators
-
Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11: 521-529.
-
(2010)
Lancet Oncol
, vol.11
, pp. 521-529
-
-
Cappuzzo, F.1
Ciuleanu, T.2
Stelmakh, L.3
-
4
-
-
84861976809
-
First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
-
Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30: 1122-1128.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1122-1128
-
-
Han, J.Y.1
Park, K.2
Kim, S.W.3
-
5
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405): An open label randomised phase 3 trial
-
West Japan Oncology Group
-
Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11: 121-128.
-
(2010)
Lancet Oncol
, vol.11
, pp. 121-128
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
-
6
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
North-East Japan Study Group
-
Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-2388.
-
(2010)
N Engl J Med
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
-
7
-
-
79960889662
-
Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study
-
Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12: 735-742.
-
(2011)
Lancet Oncol
, vol.12
, pp. 735-742
-
-
Zhou, C.1
Wu, Y.L.2
Chen, G.3
-
8
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac): A multicentre open-label randomised phase 3 trial
-
Spanish Lung Cancer Group In Collaboration With Groupe Français De Pneumo-Cancérologie And Associazione Italiana Oncologia Toracica
-
Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13: 239-246.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
9
-
-
69949186250
-
Screening for epidermal growth factor receptor mutations in lung cancer
-
Spanish Lung Cancer Group
-
Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361: 958-967.
-
(2009)
N Engl J Med
, vol.361
, pp. 958-967
-
-
Rosell, R.1
Moran, T.2
Queralt, C.3
-
10
-
-
33947498978
-
Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer
-
Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer. J Clin Oncol 2007;25: 587-595.
-
(2007)
J Clin Oncol
, vol.25
, pp. 587-595
-
-
Sequist, L.V.1
Bell, D.W.2
Lynch, T.J.3
Haber, D.A.4
-
11
-
-
21144439000
-
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
-
Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102: 7665-7670.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 7665-7670
-
-
Kwak, E.L.1
Sordella, R.2
Bell, D.W.3
-
12
-
-
84866709146
-
First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor for patients with EGFRmutant lung cancers
-
Abstract 7530
-
Kris M, Mok TS, Ou I, et al. First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor for patients with EGFRmutant lung cancers. J Clin Oncol 2012;30 (Suppl);Abstract 7530.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Kris, M.1
Mok, T.S.2
Ou, I.3
-
13
-
-
84862819699
-
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
-
Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012;13: 539-548.
-
(2012)
Lancet Oncol
, vol.13
, pp. 539-548
-
-
Yang, J.C.1
Shih, J.Y.2
Su, W.C.3
-
14
-
-
84866655838
-
LUX-lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first- line treatment for patients with advanced adenocarcinoma of the lung harbouring EGFR mutations
-
Abstract LBA7500
-
Yang JC, Schuler MH, Yamamoto N et al. LUX-lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first- line treatment for patients with advanced adenocarcinoma of the lung harbouring EGFR mutations. J Clin Oncol 2012;30 (Suppl);Abstract LBA7500.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Yang, J.C.1
Schuler, M.H.2
Yamamoto, N.3
-
15
-
-
83555166254
-
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
-
Kim ST, Uhm JE, Lee J, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012;75: 82-88.
-
(2012)
Lung Cancer
, vol.75
, pp. 82-88
-
-
Kim, S.T.1
Uhm, J.E.2
Lee, J.3
-
16
-
-
77951951659
-
Clinical outcomes in nonsmall- cell lung cancer patients with EGFR mutations: Pooled analysis
-
Paz-Ares L, Soulières D, Melezínek I, et al. Clinical outcomes in nonsmall- cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010;14: 51-69.
-
(2010)
J Cell Mol Med
, vol.14
, pp. 51-69
-
-
Paz-Ares, L.1
Soulières, D.2
Melezínek, I.3
-
17
-
-
1542503746
-
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1
-
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22: 777-784.
-
(2004)
J Clin Oncol
, vol.22
, pp. 777-784
-
-
Giaccone, G.1
Herbst, R.S.2
Manegold, C.3
-
18
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2
-
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22: 785-794.
-
(2004)
J Clin Oncol
, vol.22
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
-
19
-
-
24944440830
-
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall- cell lung cancer
-
TRIBUTE Investigator Group
-
Herbst RS, Prager D, Hermann R, et al.; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall- cell lung cancer. J Clin Oncol 2005;23: 5892-5899.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
-
20
-
-
34248140107
-
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-smallcell lung cancer: The Tarceva Lung Cancer Investigation Trial
-
Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-smallcell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25: 1545-1552.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1545-1552
-
-
Gatzemeier, U.1
Pluzanska, A.2
Szczesna, A.3
-
21
-
-
33745897599
-
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
-
Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7: 385-388.
-
(2006)
Clin Lung Cancer
, vol.7
, pp. 385-388
-
-
Davies, A.M.1
Ho, C.2
Lara Jr., P.N.3
MacK, P.4
Gumerlock, P.H.5
Gandara, D.R.6
-
22
-
-
80052972204
-
A randomized, phase II, biomarker- selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
-
Hirsch FR, Kabbinavar F, Eisen T, et al. A randomized, phase II, biomarker- selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2011;29: 3567-3573.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3567-3573
-
-
Hirsch, F.R.1
Kabbinavar, F.2
Eisen, T.3
-
23
-
-
75249084998
-
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
-
Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27: 5080-5087.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5080-5087
-
-
Mok, T.S.1
Wu, Y.L.2
Yu, C.J.3
-
24
-
-
84870825428
-
A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II
-
Abstract 7519
-
Mok T, Wu YL, Thongprasert S et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. J Clin Oncol 2012;30 (Suppl);Abstract 7519.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Mok, T.1
Wu, Y.L.2
Thongprasert, S.3
-
25
-
-
84863892117
-
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial
-
Jänne PA, Wang X, Socinski MA, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012;30: 2063-2069.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2063-2069
-
-
Jänne, P.A.1
Wang, X.2
Socinski, M.A.3
-
26
-
-
80053130032
-
Monoclonal antibodies against EGFR in non-small cell lung cancer
-
Pirker R, Filipits M. Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit Rev Oncol Hematol 2011;80: 1-9.
-
(2011)
Crit Rev Oncol Hematol
, vol.80
, pp. 1-9
-
-
Pirker, R.1
Filipits, M.2
-
27
-
-
65349116059
-
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): An open-label randomised phase iii trial
-
FLEX Study Team
-
Pirker R, Pereira JR, Szczesna A, et al.; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373: 1525-1531.
-
(2009)
Lancet
, vol.373
, pp. 1525-1531
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
-
28
-
-
77949891126
-
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099
-
Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28: 911-917.
-
(2010)
J Clin Oncol
, vol.28
, pp. 911-917
-
-
Lynch, T.J.1
Patel, T.2
Dreisbach, L.3
-
29
-
-
74049104196
-
Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small-cell lung cancer: A meta-analysis of randomized phase II/III trials
-
Abstract A3.7
-
Thatcher N, Lynch TJ, Butts CA, et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small-cell lung cancer: a meta-analysis of randomized phase II/III trials. J Thorac Oncol 2009;4 (Suppl 1):S297. Abstract A3.7.
-
(2009)
J Thorac Oncol
, vol.4
, Issue.SUPPL. 1
-
-
Thatcher, N.1
Lynch, T.J.2
Butts, C.A.3
-
30
-
-
78650694719
-
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study
-
Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011;12: 30-37.
-
(2011)
Lancet Oncol
, vol.12
, pp. 30-37
-
-
Gatzemeier, U.1
Von Pawel, J.2
Vynnychenko, I.3
-
31
-
-
79960894047
-
Molecular biomarkers in non-small-cell lung cancer: A retrospective analysis of data from the phase 3 FLEX study
-
O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12: 795-805.
-
(2011)
Lancet Oncol
, vol.12
, pp. 795-805
-
-
O'Byrne, K.J.1
Gatzemeier, U.2
Bondarenko, I.3
-
32
-
-
77949886293
-
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer
-
Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28: 918-927.
-
(2010)
J Clin Oncol
, vol.28
, pp. 918-927
-
-
Khambata-Ford, S.1
Harbison, C.T.2
Hart, L.L.3
-
33
-
-
84855311144
-
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study
-
Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13: 33-42.
-
(2012)
Lancet Oncol
, vol.13
, pp. 33-42
-
-
Pirker, R.1
Pereira, J.R.2
Von Pawel, J.3
-
34
-
-
84874106310
-
Increased EGFR gene copy number detected by fluorescence in situ hybridization predicts outcome in nonsmall cell lung cancer patients treated with cetuximab and chemotherapy
-
Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescence in situ hybridization predicts outcome in nonsmall cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2011;26: 3551-3557.
-
(2011)
J Clin Oncol
, vol.26
, pp. 3551-3557
-
-
Hirsch, F.R.1
Herbst, R.S.2
Olsen, C.3
-
35
-
-
78650515870
-
Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer
-
Schiller JH, von Pawel J, Schütt P, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5: 1977-1985.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1977-1985
-
-
Schiller, J.H.1
Von Pawel, J.2
Schütt, P.3
-
36
-
-
33644975044
-
Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): A primary analysis
-
Abstract 1123
-
Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis. Eur J Cancer 2005;3 (Suppl): 324, Abstract 1123.
-
(2005)
Eur J Cancer
, vol.3
, Issue.SUPPL.
, pp. 324
-
-
Crawford, J.1
Swanson, P.2
Prager, D.3
-
37
-
-
59149092945
-
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
-
Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27: 591-598.
-
(2009)
J Clin Oncol
, vol.27
, pp. 591-598
-
-
Fidias, P.M.1
Dakhil, S.R.2
Lyss, A.P.3
-
38
-
-
70350225538
-
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: A randomised, double-blind, phase 3 study
-
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374: 1432-1440.
-
(2009)
Lancet
, vol.374
, pp. 1432-1440
-
-
Ciuleanu, T.1
Brodowicz, T.2
Zielinski, C.3
-
39
-
-
78049401119
-
Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC)
-
Abstract 7506
-
Belani CP, Waterhouse DM, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28 (Suppl):Abstract 7506.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Belani, C.P.1
Waterhouse, D.M.2
Ghazal, H.3
-
40
-
-
70349477817
-
For the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
-
Abstract LBA8002
-
Miller VA, O'Connor P, Soh C, Kabbinavar F, for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27 (Suppl):Abstract LBA8002.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Miller, V.A.1
O'Connor, P.2
Soh, C.3
Kabbinavar, F.4
-
41
-
-
77957042719
-
Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study
-
Abstract 7507
-
Pérol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010;28 (Suppl);Abstract 7507.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Pérol, M.1
Chouaid, C.2
Milleron, B.J.3
-
42
-
-
77649203360
-
Randomized phase III trial of platinumdoublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced nonsmall- cell lung cancer: Results of a West Japan Thoracic Oncology Group trial (WJTOG0203)
-
Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinumdoublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced nonsmall- cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203). J Clin Oncol 2010;28: 753-760.
-
(2010)
J Clin Oncol
, vol.28
, pp. 753-760
-
-
Takeda, K.1
Hida, T.2
Sato, T.3
-
43
-
-
84867566940
-
PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)
-
Abstract LBA7507
-
Paz-Ares LG, De Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30 (Suppl);Abstract LBA7507.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Paz-Ares, L.G.1
De Marinis, F.2
Dediu, M.3
-
44
-
-
80054731248
-
Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer
-
Abstract LBA7511
-
Zhang L, Shenglin M, Song X, et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2011;29 (Suppl):Abstract LBA7511.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Zhang, L.1
Shenglin, M.2
Song, X.3
-
45
-
-
84863011008
-
Survival benefit with erlotinib maintenance therapy in patients with advanced nonsmall- cell lung cancer (nsclc) according to response to first-line chemotherapy
-
SATURN Investigators
-
Coudert B, Ciuleanu T, Park K, et al.; SATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced nonsmall- cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012;23: 388-394.
-
(2012)
Ann Oncol
, vol.23
, pp. 388-394
-
-
Coudert, B.1
Ciuleanu, T.2
Park, K.3
-
46
-
-
0034095853
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
-
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18: 2354-2362.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2354-2362
-
-
Fossella, F.V.1
Devore, R.2
Kerr, R.N.3
-
47
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
-
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18: 2095-2103.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
-
48
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22: 1589-1597.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
-
49
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
-
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290: 2149-2158.
-
(2003)
JAMA
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
-
50
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]
-
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21: 2237-2246.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
-
51
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537.
-
(2005)
Lancet
, vol.366
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
-
52
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
-
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372: 1809-1818.
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
-
53
-
-
84866927445
-
TAILOR: A phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC with wild-type (wt) EGFR
-
Abstract LBA7501
-
Garassino MC, Martelli O, Bettini A, et al. TAILOR: A phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC with wild-type (wt) EGFR. J Clin Oncol 2012;30 (Suppl);Abstract LBA7501.
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Garassino, M.C.1
Martelli, O.2
Bettini, A.3
-
54
-
-
84866255620
-
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
-
Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30: 3337-3344.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3337-3344
-
-
Ramalingam, S.S.1
Blackhall, F.2
Krzakowski, M.3
-
55
-
-
34548457234
-
The iaslc lung cancer staging project: Proposals for the revision of the tnm stage groupings in the forthcoming (seventh) edition of the tnm classification of malignant tumours
-
International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions
-
Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2: 706-714.
-
(2007)
J Thorac Oncol
, vol.2
, pp. 706-714
-
-
Goldstraw, P.1
Crowley, J.2
Chansky, K.3
-
56
-
-
78651083043
-
A phase III randomized, doubleblind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19
-
Abstract LBA7005
-
Goss GD, Lorimer I, Tsao MS, et al. A phase III randomized, doubleblind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol 2010;28 (Suppl 18):Abstract LBA7005.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. 18
-
-
Goss, G.D.1
Lorimer, I.2
Tsao, M.S.3
-
57
-
-
45149102984
-
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
-
Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26: 2450-2456.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2450-2456
-
-
Kelly, K.1
Chansky, K.2
Gaspar, L.E.3
-
58
-
-
84861626518
-
Efficacy of maintenance erlotinib versus placebo in patients with unresectable stage III non-small cell lung cancer following concurrent chemoradiation
-
Abstract C6.1
-
Rigas JR, Carey MA, Rubin MS, et al. Efficacy of maintenance erlotinib versus placebo in patients with unresectable stage III non-small cell lung cancer following concurrent chemoradiation. J Thorac Oncol 2009;4 (Suppl): 371, Abstract C6.1.
-
(2009)
J Thorac Oncol
, vol.4
, Issue.SUPPL.
, pp. 371
-
-
Rigas, J.R.1
Carey, M.A.2
Rubin, M.S.3
-
59
-
-
71649096662
-
Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT)
-
Abstract 7520
-
Richardson F, Richardson K,Sennello G et al. Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). J Clin Oncol 2009;27 (Suppl 15):Abstract 7520.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL. 15
-
-
Richardson, F.1
Richardson, K.2
Sennello, G.3
-
60
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
-
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354: 567-578.
-
(2006)
N Engl J Med
, vol.354
, pp. 567-578
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
-
61
-
-
79959195283
-
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324
-
Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29: 2312-2318.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2312-2318
-
-
Blumenschein Jr., G.R.1
Paulus, R.2
Curran, W.J.3
-
62
-
-
70349723488
-
Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407
-
Abstract 7505
-
Govindan R, Bogart J, Wang X, et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 2009;27 (Suppl):Abstract 7505.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Govindan, R.1
Bogart, J.2
Wang, X.3
-
63
-
-
84880111857
-
A randomized phase iii comparison of standard-dose (60 gy) versus high-dose (74 gy) conformal chemoradiotherapy +- cetuximab for stage iiiaiiib non-small cell lung cancer: Preliminary findings on radiation dose in rtog 0617
-
Miami Beach, FL; 2-6 October; Abstract LB2
-
Bradley JD, Paulus R, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy +/- cetuximab for stage IIIA/IIIB non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617. Presented at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO); Miami Beach, FL; 2-6 October2011; Abstract LB2.
-
(2011)
53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO)
-
-
Bradley, J.D.1
Paulus, R.2
Komaki, R.3
-
64
-
-
84874111218
-
-
College of American Pathologists. Lung cancer biomarkers guideline draft recommendations. Available at: http://www.cap.org/apps/docs/membership/ transformation/new/lung-public-comment-supporting- materials.pdf.
-
Lung Cancer Biomarkers Guideline Draft Recommendations
-
-
-
65
-
-
77649222572
-
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial
-
Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28: 744-752.
-
(2010)
J Clin Oncol
, vol.28
, pp. 744-752
-
-
Douillard, J.Y.1
Shepherd, F.A.2
Hirsh, V.3
-
66
-
-
80053648522
-
Erlotinib versus docetaxel or pemetrexed as second line therapy in patients with advanced non small cell lung cancer and poor prognosis: Efficacy and safety results from phase iii titan study
-
Chicago, IL; 9-11 December; Abstract LBOA5
-
Ciuleanu T, Stelmakh L, Cicenas S, et al. Erlotinib versus docetaxel or pemetrexed as second line therapy in patients with advanced non small cell lung cancer and poor prognosis: Efficacy and safety results from phase III TITAN study. Presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology; Chicago, IL; 9-11 December2010; Abstract LBOA5.
-
(2010)
Chicago Multidisciplinary Symposium in Thoracic Oncology
-
-
Ciuleanu, T.1
Stelmakh, L.2
Cicenas, S.3
-
67
-
-
33750962024
-
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
-
Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24: 5034-5042.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5034-5042
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Bunn Jr., P.A.3
-
68
-
-
22044453790
-
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
-
Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-144.
-
(2005)
N Engl J Med
, vol.353
, pp. 133-144
-
-
Tsao, M.S.1
Sakurada, A.2
Cutz, J.C.3
-
69
-
-
34347393745
-
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study
-
Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99: 838-846.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 838-846
-
-
Taguchi, F.1
Solomon, B.2
Gregorc, V.3
-
70
-
-
84867900616
-
Prognostic and predictive role of the veristrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the ncic clinical trials group br.21 trial
-
Carbone DP, Ding K, Roder H, et al. Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial. J Thorac Oncol 2012;7: 1653-1660.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 1653-1660
-
-
Carbone, D.P.1
Ding, K.2
Roder, H.3
-
71
-
-
78149249388
-
Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
-
Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28: 4769-4777.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4769-4777
-
-
Roberts, P.J.1
Stinchcombe, T.E.2
Der, C.J.3
Socinski, M.A.4
-
72
-
-
79960893966
-
Are all KRAS mutations created equal?
-
Stinchcombe TE, Der CJ. Are all KRAS mutations created equal? Lancet Oncol 2011;12: 717-718.
-
(2011)
Lancet Oncol
, vol.12
, pp. 717-718
-
-
Stinchcombe, T.E.1
Der, C.J.2
-
74
-
-
84866753892
-
KRAS wild-type lung cancer: A moving target in an era of genotype migration
-
Oxnard GR, Jänne PA. KRAS wild-type lung cancer: a moving target in an era of genotype migration. J Clin Oncol 2012;30: 3322-3324.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3322-3324
-
-
Oxnard, G.R.1
Jänne, P.A.2
-
75
-
-
84866360342
-
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas
-
Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18: 4910-4918.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4910-4918
-
-
Arcila, M.E.1
Chaft, J.E.2
Nafa, K.3
-
76
-
-
32944481596
-
Clinical course of patients with nonsmall cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
-
Riely GJ, Pao W, Pham D, et al. Clinical course of patients with nonsmall cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1): 839-844.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.3 PART 1
, pp. 839-844
-
-
Riely, G.J.1
Pao, W.2
Pham, D.3
-
77
-
-
74949110711
-
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
-
Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28: 357-360.
-
(2010)
J Clin Oncol
, vol.28
, pp. 357-360
-
-
Jackman, D.1
Pao, W.2
Riely, G.J.3
-
78
-
-
20444456682
-
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: A report of three cases
-
Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005;15: 107-111.
-
(2005)
Oncol Res
, vol.15
, pp. 107-111
-
-
Yano, S.1
Nakataki, E.2
Ohtsuka, S.3
-
79
-
-
78650660439
-
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis
-
Watanabe S, Tanaka J, Ota T, et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 2011;11: 1.
-
(2011)
BMC Cancer
, vol.11
, pp. 1
-
-
Watanabe, S.1
Tanaka, J.2
Ota, T.3
-
80
-
-
33947731875
-
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
-
Yokouchi H, Yamazaki K, Kinoshita I, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7: 51.
-
(2007)
BMC Cancer
, vol.7
, pp. 51
-
-
Yokouchi, H.1
Yamazaki, K.2
Kinoshita, I.3
-
81
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352: 786-792.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
-
82
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
-
83
-
-
79952711946
-
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
-
Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17: 1616-1622.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1616-1622
-
-
Oxnard, G.R.1
Arcila, M.E.2
Sima, C.S.3
-
84
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105: 2070-2075.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
-
85
-
-
37549061078
-
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
-
Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67: 11924-11932.
-
(2007)
Cancer Res
, vol.67
, pp. 11924-11932
-
-
Engelman, J.A.1
Zejnullahu, K.2
Gale, C.M.3
-
86
-
-
49149118719
-
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
-
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27: 4702-4711.
-
(2008)
Oncogene
, vol.27
, pp. 4702-4711
-
-
Li, D.1
Ambrogio, L.2
Shimamura, T.3
-
87
-
-
34347208648
-
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
-
Li D, Shimamura T, Ji H, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007;12: 81-93.
-
(2007)
Cancer Cell
, vol.12
, pp. 81-93
-
-
Li, D.1
Shimamura, T.2
Ji, H.3
-
88
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316: 1039-1043.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
-
89
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104: 20932-20937.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
-
90
-
-
73649102105
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
-
Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17: 77-88.
-
(2010)
Cancer Cell
, vol.17
, pp. 77-88
-
-
Turke, A.B.1
Zejnullahu, K.2
Wu, Y.L.3
-
91
-
-
56449089812
-
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
-
Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68: 9479-9487.
-
(2008)
Cancer Res
, vol.68
, pp. 9479-9487
-
-
Yano, S.1
Wang, W.2
Li, Q.3
-
92
-
-
79953118839
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
-
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.
-
(2011)
Sci Transl Med
, vol.3
-
-
Sequist, L.V.1
Waltman, B.A.2
Dias-Santagata, D.3
-
93
-
-
33745913034
-
Memorial sloan-kettering cancer center lung cancer oncogenome group. egfr mutations in smallcell lung cancers in patients who have never smoked
-
Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in smallcell lung cancers in patients who have never smoked. N Engl J Med 2006;355: 213-215.
-
(2006)
N Engl J Med
, vol.355
, pp. 213-215
-
-
Zakowski, M.F.1
Ladanyi, M.2
Kris, M.G.3
-
94
-
-
78349265779
-
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer
-
Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16: 5489-5498.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5489-5498
-
-
Suda, K.1
Murakami, I.2
Katayama, T.3
-
95
-
-
79957823572
-
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial
-
Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011;377: 1846-1854.
-
(2011)
Lancet
, vol.377
, pp. 1846-1854
-
-
Herbst, R.S.1
Ansari, R.2
Bustin, F.3
-
96
-
-
79952267022
-
Phase i dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors
-
Jänne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17: 1131-1139.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1131-1139
-
-
Jänne, P.A.1
Boss, D.S.2
Camidge, D.R.3
-
97
-
-
70349637311
-
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
-
Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20: 1674-1681.
-
(2009)
Ann Oncol
, vol.20
, pp. 1674-1681
-
-
Soria, J.C.1
Shepherd, F.A.2
Douillard, J.Y.3
-
98
-
-
79958080372
-
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib
-
Johnson ML, Riely GJ, Rizvi NA, et al. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac Oncol 2011;6: 1128-1131.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1128-1131
-
-
Johnson, M.L.1
Riely, G.J.2
Rizvi, N.A.3
-
99
-
-
79959195227
-
A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC)
-
Abstract 3017
-
Wakelee HA, Gettinger SN, Engelman JA, et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28 (Suppl):Abstract 3017.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Wakelee, H.A.1
Gettinger, S.N.2
Engelman, J.A.3
-
100
-
-
79951885125
-
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
-
Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28: 4953-4960.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4953-4960
-
-
Sequist, L.V.1
Gettinger, S.2
Senzer, N.N.3
-
101
-
-
77954584507
-
Neratinib, an irreversible pan- ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer
-
Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan- ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28: 3076-3083.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3076-3083
-
-
Sequist, L.V.1
Besse, B.2
Lynch, T.J.3
-
102
-
-
84862785051
-
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
-
Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-538.
-
(2012)
Lancet Oncol
, vol.13
, pp. 528-538
-
-
Miller, V.A.1
Hirsh, V.2
Cadranel, J.3
-
103
-
-
84870813984
-
Activity and tolerability of combined egfr targeting with afatinib (bibw 2992) and cetuximab in t790m+ nsclc patients
-
3-7 July; Amsterdam, The Netherlands; Abstract 2034
-
Horn L, Groen HJM, Smit EF, et al. Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. Presented at the 14th Conference on Lung Cancer; 3-7 July2011; Amsterdam, The Netherlands; Abstract 2034.
-
(2011)
14th Conference on Lung Cancer
-
-
Horn, L.1
Groen, H.J.M.2
Smit, E.F.3
-
104
-
-
70349684791
-
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
-
Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119: 3000-3010.
-
(2009)
J Clin Invest
, vol.119
, pp. 3000-3010
-
-
Regales, L.1
Gong, Y.2
Shen, R.3
-
105
-
-
80052591747
-
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
-
Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3: 99ra86.
-
(2011)
Sci Transl Med
, vol.3
-
-
Yonesaka, K.1
Zejnullahu, K.2
Okamoto, I.3
-
106
-
-
77957031745
-
Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
-
Abstract LBA7502
-
Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28 (Suppl 18):Abstract LBA7502.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL. 18
-
-
Schiller, J.H.1
Akerley, W.L.2
Brugger, W.3
-
107
-
-
80052511675
-
Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC
-
Abstract 7505
-
Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29 (Suppl):Abstract 7505.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Spigel, D.R.1
Ervin, T.J.2
Ramlau, R.3
-
108
-
-
31544452076
-
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
-
Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66: 944-950.
-
(2006)
Cancer Res
, vol.66
, pp. 944-950
-
-
Witta, S.E.1
Gemmill, R.M.2
Hirsch, F.R.3
-
109
-
-
84864004796
-
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-smallcell lung cancer who progressed on prior chemotherapy
-
Witta SE, Jotte RM, Konduri K, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-smallcell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012;30: 2248-2255.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2248-2255
-
-
Witta, S.E.1
Jotte, R.M.2
Konduri, K.3
-
110
-
-
80053531654
-
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFRmutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design
-
Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFRmutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17: 6298-6303.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 6298-6303
-
-
Chaft, J.E.1
Oxnard, G.R.2
Sima, C.S.3
Kris, M.G.4
Miller, V.A.5
Riely, G.J.6
-
111
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
112
-
-
72949092456
-
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
-
Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462: 1070-1074.
-
(2009)
Nature
, vol.462
, pp. 1070-1074
-
-
Zhou, W.1
Ercan, D.2
Chen, L.3
-
113
-
-
84863652136
-
Circumventing cancer drug resistance in the era of personalized medicine
-
Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012;2: 214-226.
-
(2012)
Cancer Discov
, vol.2
, pp. 214-226
-
-
Garraway, L.A.1
Jänne, P.A.2
|